Clinical trials: Inoperable Disease
Triple Negative Breast Cancer
Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
This transnational noninterventional study aims to gather real-world evidence on locally recurrent inoperable (hereafter referred to as advanced) or metastatic TNBC (a/m TNBC) biomarker testing, treatment patterns by line of…
- Trial name
- NCT07092254
- Testing
- No drug
- Where
- United States
- Volunteers
- 760 people
- Sponsor
- Daiichi Sankyo
Breast Cancer
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.
- Trial name
- TB06 (NCT07205822)
- Testing
- Dato-DXd
- Where
- 40 sites in United States, China and 4 more
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Pulmonary Hypertension
Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
The present trial investigates the long-term safety, tolerability and efficacy of bosentan in patients with inoperable CTEPH.
- Trial name
- BENEFIT OL (NCT00319111)
- Testing
- bosentan
- Volunteers
- 151 people
- Sponsor
- Actelion
Advanced, Metastatic Breast Cancer
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of Letrozole SIE (injectable) compared to Femara® (oral tablet), both given together with ribociclib, for the first-line treatment of postmenopausal women with…
- Trial name
- SIE-3 (NCT07340658)
- Volunteers
- 300 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
NF1 Mutation, Neurofibroma Plexiform
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
The main purpose of this clinical trial is to test PAS-004 in people with at least one symptomatic plexiform neurofibroma due to Neurofibromatosis Type 1 (NF1).
- Conditions
- NF1 Mutation, Neurofibroma Plexiform, Neurofibroma, Plexiform, Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)
- Trial name
- NCT06961565
- Testing
- PAS-004 Tablets, PAS-004 Capsule
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 56 people
- Sponsor
- Pasithea Therapeutics Corp.
Breast Neoplasms
A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
The purpose of the study is to: compare the chances of getting interstitial lung disease (ILD) in new users of palbociclib plus fulvestrant to new users of fulvestrant alone (using data from before palbociclib was out in the…
- Trial name
- NCT07096024
- Testing
- palbociclib plus fulvestrant, fulvestrant
- Where
- United States
- Volunteers
- 95,637 people
- Sponsor
- Pfizer
Melanoma
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The purpose of this study is to determine whether nilotinib is efficacious in the treatment of metastatic and/or inoperable melanoma harboring a c-Kit mutation.
- Trial name
- TEAM (NCT01028222)
- Testing
- Nilotinib, DTIC
- Where
- 49 sites in United States, Argentina and 12 more
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00005865
- Testing
- vinorelbine tartrate
- Where
- 50 sites in United States, Canada and 1 more
- Sponsor
- GlaxoSmithKline
Melanoma
Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma
The clinical objective of this clinical trial is to examine the clinical activity in terms of tumor response and time to treatment failure of the immunotherapeutic product GSK2132231A when given to patients with unresectable and…
- Trial name
- NCT00896480
- Testing
- Immunotherapeutic GSK2132231A
- Where
- 8 sites in Belgium, France
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Pancreatic Ductal
Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer
Investigation on safety, tolerability and efficacy of parvovirus H-1 (ParvOryx) in subjects suffering from metastatic, inoperable pancreatic cancer with at least one hepatic metastasis.
- Trial name
- ParvOryx02 (NCT02653313)
- Testing
- Parvovirus H-1 (H-1PV)
- Where
- Germany
- Volunteers
- 7 people
- Sponsor
- Oryx GmbH & Co. KG
Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
This is a clinical trial with a crossover design to determine patients' preference for capecitabine in combination with bevacizumab or everolimus in combination with exemestane for advanced breast cancer patients and to evaluate…
- Conditions
- Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast, Hormone Receptor Positive Malignant Neoplasm of Breast
- Trial name
- IMPROVE (NCT02248571)
- Testing
- Bevacizumab, Capecitabine, Everolimus
- Where
- Germany
- Volunteers
- 85 people
- Sponsor
- iOMEDICO AG
Unresectable /Inoperable Locally Advanced (Stage II-III) NSCLC and Locally Advanced LS-SCLC (Stage I-III)
CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia
This is a multi-center, non-interventional, study with the aim to access routine practice of diagnostic and treatment approaches in patients with NSCLC and SCLC in 50 largest oncology centers in Russian Federation.
- Trial name
- PASSAT (NCT05887011)
- Where
- 37 sites in Russia
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Melanoma
Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions
Study 1501-852A is a Phase 1 Study with the objective of determining safety and the highest tolerated dose of an immune response modifier cream directly applied to advanced, inoperable, melanoma skin lesions.
- Trial name
- NCT00091689
- Testing
- 852A
- Where
- 2 sites in United States
- Sponsor
- Pfizer
Intestinal Obstruction
Quality of Life in Patients With Inoperable Malignant Bowel Obstruction
The primary objective of the study is to evaluate the impact on quality of life of Lanreotide Autogel 120 mg in combination with standard care, in comparison to the standard care alone, in subjects affected by inoperable…
- Trial name
- QoL in IMBO (NCT02365584)
- Testing
- lanreotide (Autogel formulation)
- Where
- 13 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Ipsen
Breast Cancer
Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer
This study is being done to find out how safe TAS-108 is and how well TAS-108 works on recurrent or recurrent inoperable breast cancer.
- Trial name
- NCT00166543
- Testing
- TAS-108
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- SRI International
Melanoma
Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma
This is a Phase II, non-randomized, open label study of ILX651 in patients with inoperable locally advanced or metastatic melanoma. Approximately 60 patients will be enrolled in this study that is expected to last 18 months.
- Trial name
- NCT00068211
- Testing
- ILX651
- Where
- 19 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer
This is a 2-part study in patients with epidermal growth factor receptor mutation positive (EGFRm+) non-small cell lung cancer (NSCLC) whose disease has progressed on treatment with an epidermal growth factor receptor…
- Trial name
- NCT02163733
- Testing
- AZD9291 tablets, Pharmacokinetic sampling - AZD9291, Dietary Fasted
- Where
- 13 sites in France, South Korea and 2 more
- Volunteers
- 38 people
- Sponsor
- AstraZeneca
Breast Cancer
HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy
This observational study will evaluate the efficacy, safety and patient reported quality of life of palliative first-line Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) in patients with HER2-positive advanced…
- Trial name
- NCT01777958
- Where
- Germany
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Renal Cell
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally…
- Trial name
- CONTACT-03 (NCT04338269)
- Testing
- Atezolizumab, Cabozantinib
- Where
- 135 sites in United States, Argentina and 13 more
- Volunteers
- 522 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Hepatocellular
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
The study will evaluate the efficacy and safety of sunitinib (Arm A), given at 37.5 mg orally once daily, compared to sorafenib (Arm B), given orally at 400 mg twice daily, in patients with inoperable liver cancer.
- Trial name
- NCT00699374
- Testing
- sunitinib malate, sorafenib
- Where
- 171 sites in United States, Australia and 21 more
- Volunteers
- 1,075 people
- Sponsor
- Pfizer